We are live on ! Find out more
EPRS

EPIRUS BIOPHARMACEUTICALS INC COM
EPRS

Delisted

EPRS was delisted on the 3rd of August, 2016.

Back to rankings

3 hedge funds and large institutions have $44K invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% less funds holding

Funds holding: 32 → 3 (-29)

98% less capital invested

Capital invested by funds: $2.6M → $44K (-$2.55M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 29

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
-29
Holders Change %
-90.63%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
29
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CCM
Camber Capital Management
Massachusetts
-$835K
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$349K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$203K
4
VKH
Virtu KCG Holdings
New York
-$59K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$37K

EPRS Hedge Fund Activity: Q3 2016 in Review

3 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q3 2016, worth a combined $44K — down 98% from $2.6M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of EPRS and 0 opened new positions — a net loss of 29 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Camber Capital Management, exiting entirely with an estimated $835K sold.

  • 3 institutional investors held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q3 2016, down from 32 in Q2 2016.
  • Funds reported $44K of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q3 2016, down 98% quarter-over-quarter.
  • 0 funds opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q3 2016 and 29 closed out, a net change of -29 holders.
  • The largest EPIRUS BIOPHARMACEUTICALS INC COM seller in Q3 2016 was Camber Capital Management, an estimated $835K sold.

Based on aggregated 13F filings for Q3 2016.